Multicenter RCT: LED Red Light Dose-Response in Myopia Progression Control
Key facts
- Who runs it
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Where
- China7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 364 people, planned
- Started
- 1 Jan 2026
- Expected to end
- 30 Apr 2027
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Yingtong Vision Rehabilitation Instrument
- Hoya DIMS multi-point myopia defocus lens
- Record updated
- 9 January 2026
Who can take part
- Age
- 6 years to 14 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Aged 6 to 14 years old, regardless of gender
- After cycloplegic autorefraction, monocular or binocular spherical equivalent refraction (SER) meets: -6.00D ≤ SER ≤ -1.00D, and binocular best-corrected visual acuity (BCVA) ≥ 0.8 (logMAR 0.1; Snellen 20/25)
- Binocular anisometropia ≤ 1.50D; astigmatism ≤ 2.50D
- Able to understand the purpose of the study, willing to participate in this clinical verification, sign the informed consent form personally or through their legal guardian, and cooperate with the entire trial process (12 months)
Who cannot take part
- Received any of the following myopia control measures within one month (including but not limited to): low-concentration atropine eye drops, orthokeratology lenses, myopia control-related frame glasses, low-level red light therapy, defocus soft contact lenses, or defocus RGP lenses
- Neurological diseases (previous convulsion history, epilepsy, tic disorders, central nervous system developmental abnormalities) or mental and psychological diseases
- Photophobia or allergy to cycloplegic agents (e.g., tropicamide or cyclopentolate)
- Subjects with ocular diseases that may affect visual acuity or refractive error (e.g., lens disorders such as cataracts, glaucoma, macular degeneration, corneal diseases, uveitis, retinal detachment, severe vitreous opacity, etc.)
- Systemic diseases: immune system diseases, central nervous system diseases, Down syndrome, asthma, severe cardiopulmonary function impairment, severe liver and kidney dysfunction, acute or chronic sinusitis, or diabetes mellitus
- Binocular manifest strabismus or any other pathological changes of the eyeball or acute inflammatory ocular diseases
- Subjects deemed inappropriate by the investigator
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 6 and 14 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to verify the effectiveness and safety of non-laser LED red light combined with defocus lens therapy for controlling myopia progression and evaluate the impact of different intervention durations in 6-14 years old children and adolescents with myopia (spherical equivalent refraction: -6.00D ≤ SER ≤ -1.00D), regardless of gender. The main questions it aims to answer are:
Read full original descriptionShow less
[primary hypothesis or outcome measure 1]: Does the combination of Yingtong Vision Rehabilitation Instrument (non-laser LED red light) and Hoya DIMS defocus lens show non-inferior effectiveness to Hoya DIMS defocus lens alone in controlling 6-month axial length change? [primary hypothesis or outcome measure 2]: Do different single intervention durations (2min, 3min, 4min) of non-laser LED red light affect the effectiveness (e.g., axial length change at multiple time points, 12-month SER change) and safety of the combined therapy? If there is a comparison group: Researchers will compare Test Group A (2min PBM therapy + DIMS lenses), Test Group B (3min PBM therapy + DIMS lenses), Test Group C (4min PBM therapy + DIMS lenses), and Control Group D (DIMS lenses alone)] to see if the combined therapy has similar or better myopia control effects and comparable safety, and to identify the optimal intervention duration.
Participants will:
Complete screening examinations (axial length, refractive error, visual acuity, IOP, fundus photography, OCT, etc.) and sign the informed consent form.
Be randomly assigned to one of the four groups and receive the corresponding intervention (use the Yingtong Vision Rehabilitation Instrument as per group-specific duration twice a day, with ≥4-hour interval, plus DIMS lenses; or only DIMS lenses).
Attend regular follow-up visits at 30 days, 3 months, 6 months, 9 months, and 12 months for efficacy and safety assessments (including repeated ocular examinations and adverse event reporting).
Cooperate with the entire 12-month trial process and comply with the device usage specifications and follow-up requirements.
The 4 groups in the trial
- Test Group ATreatment being tested
PBM therapy with single intervention duration of 2 minutes + wearing Hoya DIMS defocus lens
Treatment: Yingtong Vision Rehabilitation Instrument and Hoya DIMS multi-point myopia defocus lens
- Test Group BTreatment being tested
PBM therapy with single intervention duration of 3 minutes + wearing Hoya DIMS defocus lens
Treatment: Yingtong Vision Rehabilitation Instrument and Hoya DIMS multi-point myopia defocus lens
- Test Group CTreatment being tested
PBM therapy with single intervention duration of 4 minutes + wearing Hoya DIMS defocus lens
Treatment: Yingtong Vision Rehabilitation Instrument and Hoya DIMS multi-point myopia defocus lens
- Control Group DExisting treatment, for comparison
Wearing Hoya DIMS defocus lens only
Treatment: Hoya DIMS multi-point myopia defocus lens
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Multicenter, Open-Label, Parallel-Group, Randomized Controlled Study Comparing the Dose-Response Relationship of LED Red Light in Controlling Myopia Progression
- Criteria questions
- Built from NCT07330180, who can take part
- Record updated
- 9 January 2026